 <h1>Entrectinib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to entrectinib: oral capsule</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, entrectinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking entrectinib:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain or tenderness</li>
<li>blurred vision</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>change in color vision</li>
<li>clay colored stools</li>
<li>confusion</li>
<li>dark urine</li>
<li>decreased appetite</li>
<li>defects in intelligence, short-term memory, learning ability, and attention</li>
<li>difficulty seeing at night</li>
<li>dizziness</li>
<li>fever</li>
<li>headache</li>
<li>increased sensitivity of the eyes to sunlight</li>
<li>itching or skin rash</li>
<li>joint pain, stiffness, or swelling</li>
<li>loss of appetite</li>
<li>lower back, side, or stomach pain</li>
<li>nausea and vomiting</li>
<li>problems with balance</li>
<li>sleepiness or unusual drowsiness</li>
<li>swelling of the feet or lower legs</li>
<li>trouble sleeping</li>
<li>unusual tiredness or weakness</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chest pain</li>
<li>decreased urine output</li>
<li>dilated neck veins</li>
<li>double vision</li>
<li>extreme fatigue</li>
<li>fainting</li>
<li>irregular breathing</li>
<li>irregular heartbeat recurrent</li>
<li>loss of memory</li>
<li>problems with memory</li>
<li>problems with speech or speaking</li>
<li>seeing double</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>swelling of the face, fingers, feet, or lower legs</li>
<li>tightness in the chest</li>
<li>trouble remembering</li>
<li>troubled breathing</li>
<li>weight gain</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of entrectinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Change or loss of taste </li>
<li>diarrhea</li>
<li>difficulty having a bowel movement (stool)</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to entrectinib: oral capsule</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (67%), lymphopenia (40%), neutropenia (28%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Pneumonia, sepsis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (e.g., musculoskeletal pain, musculoskeletal chest pain, myalgia, neck pain) (28%), fractures in children (e.g., hip, femoral or tibial shaft, bilateral femoral neck) (23%), arthralgia (21%), muscular weakness (12%), back pain (12%), pain in extremity (11%)</p>
<p><b>Common</b> (1% to 10%): Fractures in adults (e.g.  hip, femoral or tibial shaft, bilateral femoral neck)</p>
<p><b>Very rare</b> (less than 0.01%): Tumor lysis syndrome (TLS)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Vision disorders (e.g., blindness, cataract, cortical cataract, corneal erosion, diplopia, eye disorder, photophobia, photopsia, retinal hemorrhage, vision blurred, visual impairment, vitreous adhesions, vitreous detachment, vitreous floaters) (21%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hyperuricemia (52%), hypernatremia (35%), hypocalcemia (34%), hypophosphatemia (30%), hypoalbuminemia (28%), weight gain (25%), hyperkalemia (25%), anorexia (13%), dehydration (10%) </p>
<p><b>Uncommon</b> (0.1% to 1%): Tumor lysis syndrome (TLS)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Cognitive impairment (e.g., amnesia, aphasia, cognitive disorder, confusional state, delirium, disturbance in attention, hallucinations, visual hallucination, memory impairment, mental disorder, mental status changes (27%), sleep disorder (e.g., hypersomnia, insomnia, sleep disorder, somnolence) (14%), mood disorder (e.g., anxiety, affect lability, affective disorder, agitation, depressed mood, euphoric mood, mood altered, mood swings, irritability, depression, persistent depressive disorder, psychomotor retardation) (10%)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (13%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (44%), increased ALT (38%), increased alkaline phosphatase (25%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (30%), cough (24%), lung infection (e.g., lower respiratory tract infection, lung infection, pneumonia, respiratory tract infection) (10%)</p>
<p><b>Common</b> (1% to 10%): Pleural effusion, pulmonary embolism, respiratory failure, hypoxia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue/asthenia (48%), edema (e.g., face edema, fluid retention, generalized edema, localized edema, edema, edema peripheral, peripheral swelling) (40%), pyrexia (21%)<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reactions (20% or greater) are fatigue, constipation, dysgeusia, edema, dizziness, diarrhea, nausea, dysesthesia, dyspnea, myalgia, cognitive impairment, increased weight, cough, vomiting, pyrexia, arthralgia, and vision disorders.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dysgeusia (44%), dizziness (e.g., dizziness, vertigo, dizziness postural) (38%), dysesthesia (e.g., paresthesia, hyperesthesia, hypoesthesia, dysesthesia, oral hypoesthesia, palmar-plantar erythrodysesthesia, oral paresthesia, genital hypoesthesia) (34%), headache (21%), paresthesia (20%), peripheral sensory neuropathy (e.g., neuralgia, neuropathy peripheral, peripheral motor neuropathy, peripheral sensory neuropathy) (18%), ataxia (e.g., ataxia, balance disorder, gait disturbance) (18%), dysphagia (10%)</p>
<p><b>Common</b> (1% to 10%): Aphasia, fall<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (73%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypotension (e.g., hypotension, orthostatic hypotension) (18%)</p>
<p><b>Common</b> (1% to 10%): Congestive heart failure (CHF), QT interval prolongation, syncope<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (e.g., rash, rash maculopapular, rash pruritic, rash erythematous, rash papular) (11%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Constipation (46%), diarrhea (35%), nausea (34%), increased lipase (28%), increased amylase (26%), vomiting (24%), abdominal pain (e.g., abdominal pain upper, abdominal pain, lower abdominal discomfort, abdominal tenderness) (16%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Large intestine perforation<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about entrectinib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: multikinase inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Entrectinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Rozlytrek</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
<li>Solid Tumors</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to entrectinib: oral capsule</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (67%), lymphopenia (40%), neutropenia (28%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Pneumonia, sepsis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (e.g., musculoskeletal pain, musculoskeletal chest pain, myalgia, neck pain) (28%), fractures in children (e.g., hip, femoral or tibial shaft, bilateral femoral neck) (23%), arthralgia (21%), muscular weakness (12%), back pain (12%), pain in extremity (11%)</p><p><b>Common</b> (1% to 10%): Fractures in adults (e.g.  hip, femoral or tibial shaft, bilateral femoral neck)</p><p><b>Very rare</b> (less than 0.01%): Tumor lysis syndrome (TLS)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Vision disorders (e.g., blindness, cataract, cortical cataract, corneal erosion, diplopia, eye disorder, photophobia, photopsia, retinal hemorrhage, vision blurred, visual impairment, vitreous adhesions, vitreous detachment, vitreous floaters) (21%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hyperuricemia (52%), hypernatremia (35%), hypocalcemia (34%), hypophosphatemia (30%), hypoalbuminemia (28%), weight gain (25%), hyperkalemia (25%), anorexia (13%), dehydration (10%) </p><p><b>Uncommon</b> (0.1% to 1%): Tumor lysis syndrome (TLS)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Cognitive impairment (e.g., amnesia, aphasia, cognitive disorder, confusional state, delirium, disturbance in attention, hallucinations, visual hallucination, memory impairment, mental disorder, mental status changes (27%), sleep disorder (e.g., hypersomnia, insomnia, sleep disorder, somnolence) (14%), mood disorder (e.g., anxiety, affect lability, affective disorder, agitation, depressed mood, euphoric mood, mood altered, mood swings, irritability, depression, persistent depressive disorder, psychomotor retardation) (10%)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (13%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (44%), increased ALT (38%), increased alkaline phosphatase (25%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (30%), cough (24%), lung infection (e.g., lower respiratory tract infection, lung infection, pneumonia, respiratory tract infection) (10%)</p><p><b>Common</b> (1% to 10%): Pleural effusion, pulmonary embolism, respiratory failure, hypoxia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue/asthenia (48%), edema (e.g., face edema, fluid retention, generalized edema, localized edema, edema, edema peripheral, peripheral swelling) (40%), pyrexia (21%)<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reactions (20% or greater) are fatigue, constipation, dysgeusia, edema, dizziness, diarrhea, nausea, dysesthesia, dyspnea, myalgia, cognitive impairment, increased weight, cough, vomiting, pyrexia, arthralgia, and vision disorders.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dysgeusia (44%), dizziness (e.g., dizziness, vertigo, dizziness postural) (38%), dysesthesia (e.g., paresthesia, hyperesthesia, hypoesthesia, dysesthesia, oral hypoesthesia, palmar-plantar erythrodysesthesia, oral paresthesia, genital hypoesthesia) (34%), headache (21%), paresthesia (20%), peripheral sensory neuropathy (e.g., neuralgia, neuropathy peripheral, peripheral motor neuropathy, peripheral sensory neuropathy) (18%), ataxia (e.g., ataxia, balance disorder, gait disturbance) (18%), dysphagia (10%)</p><p><b>Common</b> (1% to 10%): Aphasia, fall<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (73%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypotension (e.g., hypotension, orthostatic hypotension) (18%)</p><p><b>Common</b> (1% to 10%): Congestive heart failure (CHF), QT interval prolongation, syncope<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (e.g., rash, rash maculopapular, rash pruritic, rash erythematous, rash papular) (11%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Constipation (46%), diarrhea (35%), nausea (34%), increased lipase (28%), increased amylase (26%), vomiting (24%), abdominal pain (e.g., abdominal pain upper, abdominal pain, lower abdominal discomfort, abdominal tenderness) (16%)</p><p><b>Uncommon</b> (0.1% to 1%): Large intestine perforation<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA. </p><h2>More about entrectinib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: multikinase inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Entrectinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
<li>Solid Tumors</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>